China Shineway Pharmaceutical Group Ltd

China Shineway Pharmaceutical Group Ltd maintains a strong liquidity position, with a current ratio of 3.71, indicating the company can cover its short-term liabilities more than three times over. The company's liquidity_fpt score is moderate, suggesting that while it is not at immediate risk of liquidity stress, it should continue to monitor its cash flow and working capital management. The company's debt-to-equity ratio is 0.04, which is relatively low, indicating a conservative capital structure with minimal reliance on debt financing. In terms of profitability, the company's return on equity (ROE) is 11.78%, which is a strong return relative to the industry median for pharmaceutical companies. This suggests that the company is effectively utilizing its equity to generate profits. The return on assets (ROA) is 8.81%, which is also above the industry median, indicating that the company is efficiently using its assets to generate earnings. The gross profit margin is 72.3%, which is in line with the industry average, suggesting that the company is maintaining healthy margins in its core operations. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed in the available data. This geographic concentration may expose the company to regulatory and economic risks specific to China. The company operates in a single business segment, which simplifies its operations but also means that its performance is entirely dependent on the success of its pharmaceutical business. Looking ahead, the company's revenue is expected to remain stable, with no significant growth or decline projected in the next fiscal year. The company's outlook for the current fiscal year is neutral, with no major changes expected in its revenue or profitability. The company's operating income and net income are also expected to remain relatively flat, with no significant changes in the cost structure or market conditions anticipated. The company's risk assessment indicates a medium liquidity risk, primarily due to its negative net cash position after accounting for total debt. This suggests that the company may need to manage its cash flow carefully to avoid liquidity constraints. The dilution risk is low, with no significant dilution expected in the near term. The company's capital structure remains stable, and there are no indications of imminent share issuance or dilution. The company's risk score is moderate, with no major red flags in its financial or operational performance. Recent events and filings indicate that the company has not issued any significant new products or entered into major partnerships in the recent period. The company's recent financial reports and investor relations communications have not highlighted any major strategic shifts or operational changes. The company's price target from analysts is 9.00 CNY, with a mean recommendation of 3.00, indicating a neutral outlook from the analyst community.